COMMUNIQUÉS West-GlobeNewswire

Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil
30/01/2024
The first THC containing pharmaceutical preparations produced in Brazil approved by the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria, “ANVISA”) TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- [...]
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
30/01/2024
All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash position BRAINTREE, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Microbot [...]
VPR Brands Triumphs Again in PTAB Ruling, Upholding Key Electronic Cigarette Patent
30/01/2024
The Company's Robust Patent and Trademark Portfolio and Innovation in Vaping Technologies Make it a Key Player in Product Development for Vaping Technologies, Catering to Both Nicotine and Cannabis Markets FORT [...]
Kraig Biocraft Laboratories Signs Pivotal MOU in Vietnam's Silk Production Capital
30/01/2024
ANN ARBOR, Mich., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), signs key Memorandum of Understanding (MOU) with the Vietnam Sericulture Association (VSA) and the Lam [...]
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
30/01/2024
Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc [...]
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
30/01/2024
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM ) , a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage [...]
As Omicron subvariants continue their worldwide transmission, CoVaRR-Net awarded another year of funding
30/01/2024
OTTAWA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- COVID-19, although no longer considered by the World Health Organization as a public-health emergency of international concern, remains a threat in Canada and worldwide. [...]
Alors que la transmission de sous-variants d'Omicron se poursuit dans le monde, une nouvelle année de financement est octroyée au réseau CoVaRR-Net
30/01/2024
OTTAWA, 30 janv. 2024 (GLOBE NEWSWIRE) -- La COVID-19, bien qu'elle ne soit plus considérée par l'Organisation mondiale de la Santé comme une urgence de santé publique de portée internationale, demeure une menace au [...]
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
30/01/2024
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of patients remain on [...]
Breckenridge Distillery and Breckenridge Brewery Announce Fourth Edition of Sexy Motor Oil Whiskey and New Sexy Motor Oil Beer
30/01/2024
Limited-Edition Sexy Motor Oil Whiskey and Beer Collaboration Available Exclusively at Breckenridge Distillery and Breckenridge Brewery Locations in Colorado Starting on Valentine’s Day BRECKENRIDGE, Colo., Jan. 30, [...]
Expanding Capabilities for Clients: Olon to Open New High Potency API Suite in US
30/01/2024
MILAN, Italy, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Olon Group announces the construction of a cutting-edge High Potency API suite. A GMP High Potency Active Pharmaceutical Ingredient (HPAPI) suite, currently under [...]
CorVel Announces Revenues and Earnings
30/01/2024
FORT WORTH, Texas, Jan. 30, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended December 31, 2023. Revenues for the quarter were $202 million, an increase from $179 [...]
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures
30/01/2024
Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical trials Participating investors include Roche Venture Fund, Pfizer, [...]
The Ensign Group Schedules Year-End 2023 Earnings Call for Friday, February 2, 2024
30/01/2024
SAN JUAN CAPISTRANO, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
RevoluGen Demonstrates Superior Automated Magnetic Bead-Based HMW-DNA Extraction with its Fire Monkey Chemistry Under Collaboration with LGC Biosearch Technologies
30/01/2024
HADFIELD, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- UK genomics company, RevoluGen Ltd., has demonstrated a new protocol for automated bead-based high molecular weight HMW-DNA extraction with its proprietary [...]
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies
30/01/2024
Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies. The three partners are [...]
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)
30/01/2024
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0. [...]
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)
30/01/2024
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV) Les deux groupes de traitement associant le [...]
INTERIM REPORT FOR Q1 2023/24
30/01/2024
In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT [...]

Pages